X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Pfizer with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs ADCOCK INGRAM (S. Africa) - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 PFIZER   ADCOCK INGRAM
EQUITY SHARE DATA
    PFIZER
Mar-16
ADCOCK INGRAM
Jun-14
PFIZER/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs2,724403-   
Low Rs1,611291-   
Sales per share (Unadj.) Rs440.9119.9-  
Earnings per share (Unadj.) Rs48.7-30.2-  
Cash flow per share (Unadj.) Rs75.8-25.0-  
Dividends per share (Unadj.) Rs15.000-  
Dividend yield (eoy) %0.70-  
Book value per share (Unadj.) Rs462.994.1-  
Shares outstanding (eoy) m45.75168.78-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.92.9 169.9%   
Avg P/E ratio x44.5-11.5 -387.6%  
P/CF ratio (eoy) x28.6-13.9 -206.5%  
Price / Book Value ratio x4.73.7 127.0%  
Dividend payout %30.80-   
Avg Mkt Cap Rs m99,16358,557 169.3%   
No. of employees `0002.94.3 67.3%   
Total wages/salary Rs m2,7583,675 75.0%   
Avg. sales/employee Rs Th6,981.74,714.3 148.1%   
Avg. wages/employee Rs Th954.5856.1 111.5%   
Avg. net profit/employee Rs Th771.1-1,187.9 -64.9%   
INCOME DATA
Net Sales Rs m20,17020,238 99.7%  
Other income Rs m857142 605.0%   
Total revenues Rs m21,02820,380 103.2%   
Gross profit Rs m4,310-3,507 -122.9%  
Depreciation Rs m1,239873 141.8%   
Interest Rs m5548 0.9%   
Profit before tax Rs m3,923-4,787 -82.0%   
Minority Interest Rs m0-13 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m990-   
Tax Rs m1,794299 599.9%   
Profit after tax Rs m2,228-5,100 -43.7%  
Gross profit margin %21.4-17.3 -123.3%  
Effective tax rate %45.7-6.2 -732.0%   
Net profit margin %11.0-25.2 -43.8%  
BALANCE SHEET DATA
Current assets Rs m16,29914,823 110.0%   
Current liabilities Rs m7,5948,340 91.1%   
Net working cap to sales %43.232.0 134.7%  
Current ratio x2.11.8 120.8%  
Inventory Days Days65111 58.9%  
Debtors Days Days26124 20.8%  
Net fixed assets Rs m8,6228,640 99.8%   
Share capital Rs m45894 486.9%   
"Free" reserves Rs m20,7220-   
Net worth Rs m21,18015,885 133.3%   
Long term debt Rs m255,582 0.4%   
Total assets Rs m29,13730,008 97.1%  
Interest coverage x755.5-7.7 -9,770.5%   
Debt to equity ratio x00.4 0.3%  
Sales to assets ratio x0.70.7 102.6%   
Return on assets %7.7-15.2 -50.5%  
Return on equity %10.5-32.1 -32.8%  
Return on capital %19.0-19.8 -95.9%  
Exports to sales %0.10-   
Imports to sales %17.50-   
Net fx Rs m-880-   
CASH FLOW
From Operations Rs m3,4361,727 198.9%  
From Investments Rs m-6,991-530 1,318.0%  
From Financial Activity Rs m-6195,066 -12.2%  
Net Cashflow Rs m-4,1746,263 -66.6%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.56 Rs / ZAR

Compare PFIZER With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare PFIZER With: DR. DATSONS LABS  SUVEN LIFE  ORCHID PHARMA LTD  VENUS REMEDIES  BIOCON LTD  



Today's Market

Sensex Continues Momentum; Metal Sector Up 2.5%(11:30 am)

After opening the day on a positive note, stock markets in India have continued their momentum. Sectoral indices are trading on a positive note with stocks in the metal sector.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


Feb 23, 2018 12:41 PM

TRACK PFIZER

PFIZER - AJANTA PHARMA COMPARISON

COMPARE PFIZER WITH

MARKET STATS